299 related articles for article (PubMed ID: 7794024)
21. The bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy?
Holtorf K
Postgrad Med; 2009 Jan; 121(1):73-85. PubMed ID: 19179815
[TBL] [Abstract][Full Text] [Related]
22. Exogenous progestagens and the human breast.
Sitruk-Ware R; Plu-Bureau G
Maturitas; 2004 Sep; 49(1):58-66. PubMed ID: 15351097
[TBL] [Abstract][Full Text] [Related]
23. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy.
Genazzani AR; Gadducci A; Gambacciani M
Climacteric; 2001 Sep; 4(3):181-93. PubMed ID: 11588941
[TBL] [Abstract][Full Text] [Related]
24. A physiologic role for testosterone in limiting estrogenic stimulation of the breast.
Dimitrakakis C; Zhou J; Wang J; Belanger A; LaBrie F; Cheng C; Powell D; Bondy C
Menopause; 2003; 10(4):292-8. PubMed ID: 12851512
[TBL] [Abstract][Full Text] [Related]
25. Oestrogens, progestins and breast proliferation.
Thijssen JH
Zentralbl Gynakol; 1997; 119 Suppl 2():43-7. PubMed ID: 9361394
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the proliferative effects of estradiol and conjugated equine estrogens on human breast cancer cells and impact of continuous combined progestogen addition.
Mueck AO; Seeger H; Wallwiener D
Climacteric; 2003 Sep; 6(3):221-7. PubMed ID: 14567770
[TBL] [Abstract][Full Text] [Related]
27. Reduction of human metastatic breast cancer cell aggressiveness on introduction of either form a or B of the progesterone receptor and then treatment with progestins.
Sumida T; Itahana Y; Hamakawa H; Desprez PY
Cancer Res; 2004 Nov; 64(21):7886-92. PubMed ID: 15520195
[TBL] [Abstract][Full Text] [Related]
28. Estrogen, androgen, glucocorticoid, and progesterone receptors in progestin-induced regression of human breast cancer.
Teulings FA; van Gilse HA; Henkelman MS; Portengen H; Alexieva-Figusch J
Cancer Res; 1980 Jul; 40(7):2557-61. PubMed ID: 6248208
[TBL] [Abstract][Full Text] [Related]
29. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
Cianci A; De Leo V
Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
[TBL] [Abstract][Full Text] [Related]
30. Progestin regulation of vascular endothelial growth factor in human breast cancer cells.
Hyder SM; Murthy L; Stancel GM
Cancer Res; 1998 Feb; 58(3):392-5. PubMed ID: 9458078
[TBL] [Abstract][Full Text] [Related]
31. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer.
Pasqualini JR; Chetrite GS
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):221-36. PubMed ID: 15860265
[TBL] [Abstract][Full Text] [Related]
32. Comparative cardiovascular effects of different progestins in menopause.
Rosano GM; Fini M
Int J Fertil Womens Med; 2001; 46(5):248-56. PubMed ID: 11720197
[TBL] [Abstract][Full Text] [Related]
33. Susceptibility of human breast epithelial cells in vitro to hormones and drugs.
Calaf GM
Int J Oncol; 2006 Feb; 28(2):285-95. PubMed ID: 16391781
[TBL] [Abstract][Full Text] [Related]
34. Estrogen-induced loss of progesterone receptor expression in normal and malignant ovarian surface epithelial cells.
Mukherjee K; Syed V; Ho SM
Oncogene; 2005 Jun; 24(27):4388-400. PubMed ID: 15806153
[TBL] [Abstract][Full Text] [Related]
35. Oestrogens and progestins in relation to human cancer.
IARC Monogr Eval Carcinog Risk Chem Hum; 1979 Dec; 21():83-129. PubMed ID: 397183
[TBL] [Abstract][Full Text] [Related]
36. Effect of 17 beta-estradiol, progesterone, synthetic progestins, tibolone, and tibolone metabolites on vascular endothelial growth factor mRNA in breast cancer cells.
Mirkin S; Wong BC; Archer DF
Fertil Steril; 2005 Aug; 84(2):485-91. PubMed ID: 16084894
[TBL] [Abstract][Full Text] [Related]
37. p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells.
Liang Y; Wu J; Stancel GM; Hyder SM
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):173-82. PubMed ID: 15860260
[TBL] [Abstract][Full Text] [Related]
38. [Contraception without risk of breast disease: epidemiologic and physiopathologic arguments].
Le Coutour X
NPN Med; 1985 Apr; 5(88):471-6. PubMed ID: 12315304
[TBL] [Abstract][Full Text] [Related]
39. Progestins inhibit the growth of MDA-MB-231 cells transfected with progesterone receptor complementary DNA.
Lin VC; Ng EH; Aw SE; Tan MG; Ng EH; Chan VS; Ho GH
Clin Cancer Res; 1999 Feb; 5(2):395-403. PubMed ID: 10037189
[TBL] [Abstract][Full Text] [Related]
40. Dose-dependent changes of the ratio of apoptosis to proliferation by norethisterone and medroxyprogesterone acetate in human breast epithelial cells.
Seeger H; Rakov V; Mueck AO
Horm Metab Res; 2005 Aug; 37(8):468-73. PubMed ID: 16138258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
